Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_4
2
67%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Completed1
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (33.3%)
Phase 42 (66.7%)

Trials by Status

completed133%
unknown133%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_4

GRASSP: Gralise® for Spine Surgery Pain

NCT01764464
unknownphase_3

Once Daily Gabapentin in the Treatment of Post Amputation Pain

NCT01776671
terminatedphase_4

Efficacy of Gralise® for Chronic Pelvic Pain

NCT01678911

Clinical Trials (3)

Showing 3 of 3 trials
NCT01764464Phase 4

GRASSP: Gralise® for Spine Surgery Pain

Completed
NCT01776671Phase 3

Once Daily Gabapentin in the Treatment of Post Amputation Pain

Unknown
NCT01678911Phase 4

Efficacy of Gralise® for Chronic Pelvic Pain

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3